Salsalate
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Salsalate: From Rheumatoid Arthritis to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Salsalate is an oral salicylate anti-inflammatory drug, originally used for rheumatoid arthritis, osteoarthritis and other joint conditions. The TxGNN model predicts it may be effective for Acromesomelic Dysplasia, Hunter-Thompson Type, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, osteoarthritis, arthropathy (from the knowledge graph; no approved indication text is available in the US license record) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 (cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug. Based on known information, salsalate is a salicylate prodrug with NF-κB inhibitory and AMPK-activating activity. Its efficacy in joint inflammation and pain is the basis of its original indications.
Hunter-Thompson type acromesomelic dysplasia is a rare skeletal dysplasia caused by loss-of-function mutations in CDMP1/GDF5, which disrupt BMP signaling and cartilage formation. No plausible mechanistic link between salsalate and GDF5/BMP signaling has been established. The high score most likely reflects network proximity to the arthropathy and skeletal disease cluster in the knowledge graph, not a causal pathway. This prediction should be regarded as a hypothesis only.
Other predictions for this drug were also reviewed. All are L5 and rated Hold. The most biologically plausible is spondyloarthropathy, susceptibility to (score 99.55%), because NSAID-type drugs are standard symptomatic therapy in spondyloarthritis. This would be class-based extrapolation from other NSAIDs and still needs a targeted literature search. The next closest is pseudoachondroplasia (99.78%), where salsalate might relieve secondary joint pain, though it would not address the underlying disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not available (cancelled) | Salsalate (Amneal Pharmaceuticals LLC) | Tablet (oral) | Not available |
Safety Considerations
- Contraindications flagged in the knowledge graph (these come from drug-disease relationships in the graph, not from label text): liver failure, liver disease, kidney disease, gallbladder disease, active peptic ulcer disease, gastritis, gastroesophageal reflux disease, esophagitis, blood coagulation disorders (including hemophilia, congenital prothrombin deficiency, vitamin K deficiency hemorrhagic disease), thrombocytopenic purpura, anemia, cardiovascular and heart disease, diabetes mellitus and diabetic ketoacidosis, thyroid overactivity (hyperthyroidism, Graves disease, thyrotoxicosis), and nasal polyps.
- Drug Interactions: The data compiled for this report show 100 recorded interactions, and 20 are listed. Most are Moderate:
- Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide
- Other salicylate and aminosalicylate drugs: mesalazine, balsalazide
- Blood glucose-lowering drugs: chlorpropamide, glimepiride, repaglinide, insulin aspart, insulin degludec, insulin detemir
- Bowel preparations and alkalinizing agents: potassium citrate, picosulfuric acid, sodium sulfate, polyethylene glycol with electrolytes
- Minor interactions: proton pump inhibitors (rabeprazole, dexlansoprazole, omeprazole)
Please refer to the package insert for official warnings and contraindications, because label data were not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a knowledge-graph score, with no clinical trials or literature. It has no plausible mechanistic link to the underlying genetic defect. Salsalate is also cancelled-only in the US market, so there is no marketed product to build on.
To proceed, the following is needed:
- A targeted literature and trial search for each predicted indication, especially spondyloarthropathy, where NSAID-class evidence could support an upgrade to L4
- Detailed mechanism of action data
- FDA package insert warnings and contraindications for safety screening
- Confirmation of the regulatory and supply situation, given the cancelled US license
- Route and formulation compatibility assessment for any candidate indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.